The role of thymectomy in the treatment of myasthenia gravis (MG) was analysed in 400 patients affected with generalised MG operated on between 1974-83, and prospectively followed up for five years after surgery. The occurrence of stable remission (SR) (that is, complete clinical drug-free remission that remains stable for all the subsequent follow up) was the endpoint of survival analyses and the distribution of SR time (SRT, that is, the interval from thymectomy to the occurrence of SR) was assessed by actuarial and Cox multivariate analyses. SRT distribution after surgery showed a slow progressive increase of cumulative SR rate that could both be ascribed to a delayed effect of thymectomy as well as reflect the natural history of MG, itself characterised by an increasing probability of spontaneous remission with time.
Abstract
The role of thymectomy in the treatment of myasthenia gravis (MG) was analysed in 400 patients affected with generalised MG operated on between 1974-83, and prospectively followed up for five years after surgery. The occurrence of stable remission (SR) (that is, complete clinical drug-free remission that remains stable for all the subsequent follow up) was the endpoint of survival analyses and the distribution of SR time (SRT, that is, the interval from thymectomy to the occurrence of SR) was assessed by actuarial and Cox multivariate analyses. SRT distribution after surgery showed a slow progressive increase of cumulative SR rate that could both be ascribed to a delayed effect of thymectomy as well as reflect the natural history of MG, itself characterised by an increasing probability of spontaneous remission with time. SRT distribution was similar after stratification for all variables studied except when patients without thymoma were stratified for the need for immunosuppressive treatment in addition to thymectomy. Patients without thymoma who did not require additional immunosuppressive therapy (n = 130) had the highest SR rate occurring in the two years after thymectomy, and differed from patients treated with immunosuppressive drugs who showed the highest SR rate five years after surgery. Actuarial analysis has therefore identified a subgroup of patients where SR, occurring in the first years after surgery, is more likely to be ascribed to thymectomy than merely reflect the natural course of the disease.
Myasthenia gravis (MG) is an autoimmune disease of the neuromuscular junction in which the thymus gland seems to play an important pathogenetic role. Based on histological'2 and immunological"'0 abnormalities of the myasthenic thymus, and on the excellent outcome reported in many series of surgically treated patients,"'130 thymectomy is now generally accepted as the mainstay of therapy of MG.3'-34
The effects of a therapeutic approach on the natural course of MG may be difficult to evaluate: after a few initial years of deterioration, the disease stabilises and often shows a spontaneous improvement with some probability of Thymectomy was always performed by the same surgeon (GM). In all the patients without radiological evidence of a thymoma the surgical approach to the thymus was obtained through a cosmetic collar incision low in the neck, the inferior skin flap being raised and dissected from the sternum that was split for a length of 8-10 cm. A specially developed Vshaped sternal retractor with two non parallel branches was applied to separate the split bone allowing a wide exposure of the thymic bed. This partial median sternotomy4" allows a good visualisation of the two thymic lobes, both pleural surfaces, and the pericardium. All the fat between the two phrenic nerves was removed with the gland, an effort being made to remove all thymic tissue and suspicious looking fat of the anterior mediastinum. 
Actuarial analysis of the occurrence of remissions following thymectomyfor myasthenia gravis in 400 patients When needed (especially in elderly or obese patients, or in the case of a thymoma) a total median sternotomy was performed.
Patients were prospectively followed up after thymectomy with at least one yearly visit for the first five years after surgery, and placed at the time of the visit in one of the following categories: Remission: full working life with no restriction and no subjective myasthenic symptoms for at least six months without drug treatment. A small degree of permanent objective weakness, unrelieved by neostigmine, is permitted. Improved: no symptoms or signs but still on drug treatment, or still symptomatic but in a milder stage than before thymectomy. Unchanged: minimal or equivocal changes. Worsened: definitely worse than before surgery. Postoperative death: postoperative complication (respiratory, cardiac or septic) occurring within 30 days from surgery. Death from MG: if death occurred after a progressive clinical deterioration with respiratory distress and final respiratory failure and/or cardiac arrest.
Death not related to MG.
The decision to introduce immunosuppressive treatment in addition to thymectomy was made during follow up if the patient met one of the following prospectively defined criteria: a) definite worsening with severe bulbar symptoms (or respiratory insufficiency), unresponsiveness to increased doses of anticholinesterases, occurred after thymectomy; b) clinical status was unchanged two years after surgery; c) severe bulbar symptoms (or respiratory ted before surgery in 32% of these patients, within two years from surgery in 7%, and later in the remaining 61%.
At the final assessment (n = 388, death not related to MG excluded) (table) 27% patients were in SR, 57% were improved 11 % unchanged or worse. Postoperative mortality was 2% and overall mortality related to MG 3%. Both mortality rates were significantly higher (p < 0-01) (Chi-squared test with Yates' adjustment for continuity) in the thymomatous patients.
The main factor significantly influencing the SRT distribution was the presence ofthymoma both in unifactorial (p = 0-0003) and in multifactorial (p = 0-0003) analysis. Patients with thymoma had a lower SR rate than those without (12% vs 31%). In the presence of thymoma the occurrence of SR was not influenced by any of the variables studied.
In patients without thymoma the age at disease onset and the latency of surgery significantly influenced the SRT distribution.
Patients younger than 30 at disease onset had a significantly shorter SRT (p = 0-01) than that of the older patients, and the mean age at disease onset of patients who achieved SR is lower than that of patients not in SR (26- disease onset (with cut-offvalue of30), sex, and number of germinal centres, yielded SRT distribution similar to that of the entire group of nonthymomatous patients. Conversely, stratification according to the need for immunosuppressive therapy in addition to thymectomy (since both the time of onset of immunosuppressive treatment before or after thymectomy and the different immunosuppressive regimes did not influence SRT distribution, all the patients that were administered immunosuppressive therapy were computed together) yielded two completely different curves (fig 1) , showing only one sharp increase ofthe SR rate, each curve in a different point: between first and second year of follow up for patients without additional immunosuppressive therapy, and between fourth and fifth year of follow up for the others. These two curves are significantly different according to the generalised Wilcoxon test (p < 0-005). Patients with thymoma. Actuarial analysis shows, in these patients, that cumulative SR rate progressively increases with time after surgery without abrupt slope changes (fig 2) . Stratification according to each of the variables deemed ofpossible importance in the prognosis yielded temporal patterns of SR rate similar to that of the entire group of patients with thymoma and without significant differences between subgroups. Most (79%) of these patients required immunosuppressive treatments in addition to thymectomy and the plots of the actuarial curves of patients with or without additional immunosuppressive therapy did not significantly differ, again showing a slow progressive increase with time after surgery (fig 2) , similarly to the entire group of patients with thymomatous MG. 
Discussion
studies where thymectomy is reserved for patients who failed to respond to medical treatment3046 or when transcervical thymectomy,2027 which may result in subtotal thymus removal,29 4852 is used. There seems to be a direct relationship between outcome and the extent of thymectomy,1820 28 29 and the highest remission rates (46-59%) were reported by studies which used the extended transsternal thymectomy.8 24 2 2 This suggests that the partial transsternal approach used in this study did not always result in a total thymectomy. In addition the remission rate reported in our study may depend on the restrictive definition of stable remission which includes not only clinical and pharmacological criteria but also a prolonged temporal criterion.
On unifactorial and multifactorial analysis the presence of a thymoma was associated with a lower remission rate and a higher mortality than in patients without thymoma. This agrees with all previous reports,12 14 16 17 20-25 29 30 33 37 38 46 indicating that in patients with thymoma MG is more severe and probably little influenced by thymomectomy which is, however, necessary to remove the tumour.21222952 Unifactorial and multifactorial analyses indicated that, in patients with thymomatous MG, such a poor prognosis was unaffected by all the other variables studied.
In patients without thymoma the multifactorial analysis indicated that the occurrence of SR was significantly influenced by the latency of surgery, the need for immunosuppressive treatments in addition to thymectomy, and the age at disease onset. Patients who did not require additional immunosuppressive therapy and were operated on early in the course of the disease (that is, within one year from onset) had an SR rate of 44% compared with 26% of the others (p < 004) (Chi-squared test). An early thymectomy is advocated by most reports12 16 17 20 21 24 26 27 34 5355 and probably prevents extra-thymic tissue developing autonomous autoimmune activity.45657 In addition, a young age (below the age of 30) at disease onset further increased the SR rate-patients who did not require additional immunosuppressive treatment, who had early thymectomy and were below 30 years of age at disease onset had an SR rate of 59% compared with 26% of the others (p < 0-0l) ( Actuarial analysis is probably the best available statistical method to describe the chronological correlations between the occurrence of remission and thymectomy. In our study this analysis has shown that in patients without thymoma the temporal patterns of the occurrence of SR after surgery were significantly different in the groups with or without additional immunosuppressive therapy. Patients who required immunosuppressive treatments in addition to thymectomy displayed an SR rate progressively increasing with time after thymectomy with a late more pronounced increase between fourth and fifth year after surgery, while patients who were treated only with thymectomy and anticholinesterases showed an SR rate sharply increasing in the two years immediately after surgery and then showing only slight further increments (fig 1) . Only the subgroup of patients without thymoma and whose response to thymectomy was good enough not to require further immunosuppressive treatment had such a peculiar increase of SR rate in the two years after surgery. Most (69%) of these patients in remission had been thymectomised within one year from disease onset, and therefore reached a stable remission in the first years of the course of the disease when maximum disease severity, crises, and even death are to be expected from the natural history of MG.2' 22 3435 373858
In conclusion, actuarial analysis of remission rate after surgery27 29 30 usually demonstrates a progressive increase with time that could both be the effect ofthymectomy as well as reflect the 21 2234 35 3738 natural history of the disease.
In our analysis, stratification of data has identified a subgroup of patients without thymoma and who did not require immunosuppressive treatments in addition to thymectomy who had a number of early stable remissions significantly higher than other subgroups. Such early stable remissions are not predictable simply on the basis of the natural course of MG and, since they occurred in the years immediately after surgery, they are probably to be ascribed to thymectomy. Transsternal extended thymectomy, that is supposed to assure total thymus removal reliably, yields a high remission rate with usually most remissions occurring in the first two to three years after surgery, often without additional immunosuppressive treatments.'82429 Conversely, the plot of remission rate after cervical thymectomy,'8 20 27 where total thymus removal is less probable, shows a slowly progressive increase after surgery that can be equally ascribed to thymectomy, additional immunosuppressive therapy, time alone, or all these factors.
In our series, where an effort was made to 
